lonafarnib has been researched along with Multiple Myeloma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; David, E; Khuri, FR; Lonial, S; Sun, SY; Waller, EK | 1 |
| Baulch-Brown, C; Ma, D; Molloy, TJ; Spencer, A; Yeh, SL | 1 |
2 other study(ies) available for lonafarnib and Multiple Myeloma
| Article | Year |
|---|---|
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
Topics: Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Phosphorylation; Piperidines; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured | 2005 |
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Imidazoles; Indoles; Mevalonic Acid; Multiple Myeloma; Piperidines; Pyridines; Structure-Activity Relationship; Zoledronic Acid | 2007 |